MILD RENAL DYSFUNCTION IN PATIENTS WITH ESSENTIAL HYPERTENSION: CLINICAL SIGNS AND DRUG THERAPY
https://doi.org/10.24884/1561-6274-2004-8-3-15-21
Abstract
Mild renal dysfunction in patients with essential hypertension: clinical signs and drug therapy.
About the Authors
O. B. Kuzmin
Оренбургская государственная медицинская академия
Russian Federation
Russian Federation
M. O. Pugaeva
Оренбургская государственная медицинская академия
Russian Federation
Russian Federation
S. V. Chub
Оренбургская государственная медицинская академия
Russian Federation
Russian Federation
References
1. Ruilope LM ,Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 2001; 12 (2): 218225
2. Ruilope LM, Palmer C, de Leeuw P et al. Evaluation of different parameters of renal function as a predictors of primary outcome in the INSIGHT study. J Hypertens 2001; 12 [Suppl 2]: 223
3. Mann JFE, Gerstein HC, Poque J et al. Renal insufficiency as predictor of cardiovascular outcomes and impact of ramipril: The HOPE randomization trial. Ann Intern Med 2001; 134 (8): 629636
4. Palatini P, Graniero GR, Mormino P et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from Hypertension and Ambulatory Recording Venetia Study (HARVEST). Am J Hypertens 1996; 9 (4): 334341
5. Pontremoli R, Sofia A, Ravera M et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: A Genoa Investigation on Complication. Hypertension 1997; 30 (5): 11351143
6. Osicka TM, Comper WD. Protein degradation during renal passage in normal kidney is inhibited in experimental albuminuria. Clin Sci 1997; 93 (1): 6572
7. Wachtell K, Olsen MH, Dahlof B et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hyperthrophy: the LIFE study. J Hypertens 2001; 20 (3): 353355
8. Donelly R, Rea R. Microalbuminuria: how informative and reliable are individual measurements? J Hypertens 2003; 21 (7): 12291233
9. Pontremoli R, Ravera M, Bezante GP et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17 (7): 9931000
10. Terpstra WF, May JF, Smit AJ et al. Microalbuminuria is related to marked end organ damage in previously untreated elderly hypertensive patients. Blood Press 2002; 11 (2): 8490
11. Wachtell K, Palmieri V, Olsen MH et al. Urine albumin / creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143 (2): 319326
12. Jensen JS, FeldtRasmussen B, Strandgaard S et al. Arterial hypertension, microalbuminuria and risk of ischemic heart desease. Hypertension 2000; 35 (4): 898903
13. Nakamura S, Kawano Y, Inenaga I et al. Microalbuminuria and cardiovascular events in elderly hypertensive patients without previous cardiovascular implications. Hypertens Res 2003; 26 (8): 603608
14. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139 (11): 901906
15. Romundstadt S, Holmen J, Hallan H et al. Microalbuminuria and allcause mortality in treated hypertensive individuals: does sex matter? The NordTrondelag Health Study (HUNT), Norway. Circulation 2003; 108 (22): 2783 2789
16. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to doubleblind treatment with longacting calciumchannel blocker or diuretic in International Nifidipine GITS study: Intervention as a goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356 (9228): 366372
17. Luque V, GarsiaRobles R, Tamargo J, Ruilope LM. Blood pressure control in hospital located hypertension units [Abstract]. Hypertension 2001; 37: 1030.
18. Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13 [Suppl 3]: S165S168
19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 3141
20. VounierVehier C, Amah G, Duquenoy S et al. Is assessment of kidney involvement in patients with essential hypertension satisfactory? General medical observation results of national study (PHENOMEN). Arch Mal Coeur Vaiss 2003; 96 (78): 792 799
21. Leoncini G, Viazzi F, Parodi D et al. Mild renal dysfunction and cardiovascular risk in hypertensive patients. J Am Soc Nephrol 2004; 15 [Suppl 1]: S88S90
22. de Leeuw PW, Thijs L, Birkenhager WH et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the SystEur Ttrial. J Am Soc Nephrol 2002; 13 (9): 22132222
23. Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 12061252
24. Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 10111053
25. Кузьмин ОБ, Пугаева МО. Дисфункция почки при хронической сердечной недостаточности: теоретические и клинические аспекты. Нефрология 2003; 7 (2): 3137
26. Кузьмин ОБ. Дисфункция почек при сердечной не достаточности и ее лекарственная коррекция. Медицина, М., 2003; 152
27. Кузьмин ОБ, Пугаева МО. Нейрогуморальный дисбаланс как причина дисфункции почек при первичной артериальной гипертонии. Нефрология 2004; 8 (1): 1925
28. Simons JL, Provoost AP, Anderson S et al. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 1994; 46 (3): 396404
29. Durvasula RV, Petermann AT, Hiromura K et al. Activation of local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65 (1): 3039
30. Gruden G, Zonca S, Hayward A et al. Mechanical stretch induced fibronectin and TGFІ1 in human mesangial cells is p38 mitogenactivated protein kinase dependent. Diabetes 2000; 49 (4): 655661
31. Asselbergs FW, de Boer RA, Diercks GF et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004; 93 (23): 211215
32. Ciriello J, de Oliveira CV. Renal afferents and hypertension. Curr Hypertens Rep 2002; 4 (2): 136142
33. Augustyniak RA, Tuncel M, Zhang W et al. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002; 20 (1): 39
34. Арутюнов ГП, Чернявская ТК, Лукичева ТИ. Микро альбуминурия: клинические аспекты и пути медикаментоз ной коррекции. Клин фарм тер 1999; 8 (3): 2328
35. Douglas J G, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003; 83 (Suppl): S74S76
36. Ruilope LM. New European guidelines for the management of hypertension: what is relevant for the nephrologists? Nephrol Dial Transplant 2004; 19 (3): 524528
Review
For citations:
Kuzmin O.B., Pugaeva M.O., Chub S.V. MILD RENAL DYSFUNCTION IN PATIENTS WITH ESSENTIAL HYPERTENSION: CLINICAL SIGNS AND DRUG THERAPY. Nephrology (Saint-Petersburg). 2004;8(3):15-21. (In Russ.) https://doi.org/10.24884/1561-6274-2004-8-3-15-21
Views:
269
Email this article 